Skye Bioscience, Inc. (NASDAQ:SKYE – Get Free Report)’s share price was down 9.2% during trading on Wednesday . The company traded as low as $6.33 and last traded at $6.35. Approximately 593,578 shares were traded during mid-day trading, an increase of 284% from the average daily volume of 154,743 shares. The stock had previously closed at $6.99.
Analyst Ratings Changes
A number of analysts have weighed in on SKYE shares. JMP Securities assumed coverage on shares of Skye Bioscience in a research report on Tuesday. They set an “outperform” rating and a $15.00 target price for the company. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $14.00 price objective on shares of Skye Bioscience in a research note on Friday, September 6th. Finally, Craig Hallum began coverage on shares of Skye Bioscience in a research note on Tuesday, July 9th. They set a “buy” rating and a $18.00 target price for the company. Five investment analysts have rated the stock with a buy rating, According to MarketBeat.com, Skye Bioscience has a consensus rating of “Buy” and an average price target of $18.40.
View Our Latest Stock Analysis on Skye Bioscience
Skye Bioscience Stock Down 9.2 %
Skye Bioscience (NASDAQ:SKYE – Get Free Report) last released its quarterly earnings data on Friday, August 9th. The company reported ($0.20) earnings per share for the quarter, meeting the consensus estimate of ($0.20). On average, equities analysts anticipate that Skye Bioscience, Inc. will post -1.06 EPS for the current year.
Institutional Investors Weigh In On Skye Bioscience
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Cubist Systematic Strategies LLC bought a new stake in shares of Skye Bioscience during the second quarter valued at approximately $30,000. Point72 DIFC Ltd bought a new position in shares of Skye Bioscience in the 2nd quarter worth $48,000. Rhumbline Advisers acquired a new stake in Skye Bioscience in the 2nd quarter valued at $158,000. AdvisorShares Investments LLC bought a new stake in Skye Bioscience during the 2nd quarter valued at $210,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in Skye Bioscience during the second quarter worth $222,000. 21.09% of the stock is owned by institutional investors.
Skye Bioscience Company Profile
Skye Bioscience, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes cannabinoid-based molecules for the treatment of infectious diseases. The company's lead product candidate is SBI-100 used in the treatment of glaucoma and ocular hypertension. It is also developing SBI-200 to treat and manage various eye diseases, including uveitis, dry eye syndrome, macular degeneration and diabetic retinopathy.
Read More
- Five stocks we like better than Skye Bioscience
- Stock Average Calculator
- Goldilocks CPI Report Leads Market to Sell Off, Lower Lows Ahead
- Most Volatile Stocks, What Investors Need to Know
- GameStop: Earnings Won’t Save It, Dilution Points to Trouble
- What Investors Need to Know to Beat the Market
- Dividend Aristocrats or Dividend Kings: Which Is Best for You?
Receive News & Ratings for Skye Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Skye Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.